Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research report sent to investors on Wednesday.

SRPT has been the subject of several other research reports. Evercore ISI lowered their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Raymond James reiterated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Royal Bank of Canada restated an “outperform” rating and set a $182.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 21st. UBS Group lifted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Finally, Robert W. Baird decreased their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $181.33.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $114.23 on Wednesday. The company has a market cap of $10.91 billion, a price-to-earnings ratio of 91.38 and a beta of 0.81. Sarepta Therapeutics has a 1 year low of $78.67 and a 1 year high of $173.25. The stock’s 50 day simple moving average is $122.00 and its two-hundred day simple moving average is $131.56. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Activity

In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Capital International Investors grew its position in Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after purchasing an additional 76,032 shares during the period. Janus Henderson Group PLC grew its holdings in Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock worth $544,408,000 after acquiring an additional 543,143 shares during the period. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after acquiring an additional 665,087 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after acquiring an additional 1,243,427 shares during the period. Finally, Geode Capital Management LLC boosted its position in Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.